Accéder au contenu:

Résumé de recherche

Oscillometry is increasingly adopted in respiratory clinics, however many recommendations regarding measurement settings and quality control remain subjective. The aim of this study was to investigate the optimal number of measurements and acceptable within-session coefficient of variation (CoV) in health, asthma and COPD.

Fifteen healthy, 15 asthma and 15 COPD adult participants were recruited. Eight consecutive 30 s measurements were made using an oscillometry device (tremoFlo C-100, Thorays Thoracic Medical Systems Inc., Canada) from which resistance at 5 Hz (Rrs5) was examined. The effect of progressively including a greater number of measurements on Rrs5 and its within-session coefficient of variation (CoV) was investigated. Data was analysed using one-way repeated measures ANOVA with Bonferroni post-hoc test.

The CoV(Rrs5) of the first 3 measurements was 6.7±4.7%, 9.7±5.7%, and 12.6±11.2% in healthy, asthma and COPD participants, respectively. Both mean Rrs5 and CoV(Rrs5) were not statistically different when progressively including 4–8 measurements. Selecting the 3 closest Rrs5 values over an increasing number of measurements progressively decreased the CoV(Rrs5). In order for ≥95% of participants to fall within a target CoV(Rrs5) of 10%, ≥4, 5 and 6 measurements were needed in health, asthma, and COPD, respectively.

Within-session variability of oscillometry is increased in disease. Furthermore, the higher number of measurements required to achieve a set target for asthma and COPD patients may not be practical in a clinical setting. Provided technical acceptability of measurements is established, i.e. by removing artefacts and outliers, then a CoV of 10% is a marker of quality in most patients, but we suggest higher CoVs upto 15–20% should still be reportable.


This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

Conflict of interest: Dr Harkness has nothing to disclose, however, is currently an employee of GSK, however the work in this manuscript was conducted prior to that employment.

Conflict of interest: Kieran Patel has nothing to disclose.

Conflict of interest: Farid Sanai has nothing to disclose.

Conflict of interest: Dr. Rutting has nothing to disclose.

Conflict of interest: Dr. Cottee has nothing to disclose.

Conflict of interest: Dr. Farah has nothing to disclose.

Conflict of interest: Robin Schoeffel has nothing to disclose.

Conflict of interest: Dr. King reports grants, personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, MundiPharma and Novartis; and 2) unrestricted research grants from: NHMRC, Boehringer Ingelheim, CycloPharma, GlaxoSmithKline, Menarini, MundiPharma, Philanthropic individuals and societies, non-financial support and other from Restech, Italy during the conduct of the study.

Conflict of interest: Dr. Thamrin has a patent WO 2006130922 A1 issued which is broadly relevant to the work. In addition, Dr. Thamrin has intellectual property arrangements with Thorasys Medical Systems and Restech srl relating to research collaborations, but does not have any financial relationships with either company.


Harkness LM, Patel K, Sanai F, Rutting S, Cottee AM, Farah CS, et al. Within-session variability as quality control for oscillometry in health and disease. ERJ Open Res [Internet]. 2021 Jun 17 [cited 2021 Aug 3];7(3):00074–2021

Nous contacter
Dites-nous comment nous pouvons vous aider. Nous serions heureux d'avoir de vos nouvelles !
Vous êtes intéressés par les produits THORASYS ? Contactez-nous pour obtenir un devis personnalisé.
Formulaire soumis avec succès !
Nous vous contacterons sous peu.